Medication for Opioid Use Disorder

November 25, 2019 Policy Watch

Revisions to 42 CFR Patient Confidentiality Rules for Substance Use Disorder: What It Means for Health Services Researchers

In August 2019 the United States Substance Abuse and Mental Health Services Administration (SAMHSA) proposed a revision to the Federal rule that protects patient confidentiality for people with substance use disorders, referred to as 42 CFR Part 2. The sixty day comment period has ended and comments are currently under consideration. This proposal seeks to facilitate disclosure […]

September 11, 2019 Collaborations

Achieving Value in Substance Use Disorder Treatment: Paying for What Works (and Not Paying for What Doesn’t): Workshop Summary

More than 100 policymakers, practitioners, and researchers discussed and debated how payment policy can promote evidence-based, cost-effective substance use disorder treatment, in a recent workshop hosted by the Center for Health Economics of Treatment Interventions for Substance Use Disorder, HCV and HIV (CHERISH) and the Leonard Davis Institute of Health Economics at the University of […]

July 26, 2019 Collaborations

CHERISH Workshop Addresses an ‘Unfortunate Reality’ of the Addiction Treatment Industry

Funded by the National Institute on Drug Abuse and established in 2015, CHERISH is a five year collaboration of researchers from the Leonard Davis Institute of Health Economics (LDI) of the University of Pennsylvania, Weill Cornell Medical College, Boston Medical Center, and the University of Miami. Their work is focused on studying the health economics […]

July 16, 2019 Research Highlight

Care Integration of Hepatitis C and Opioid Use Disorder Treatment is Cost-Effective and Improves Health Outcomes

People who inject drugs (PWID) often become infected with HIV and hepatitis C virus (HCV). While hepatitis C can be successfully treated with medication, care is often fragmented and rarely integrated within one program or setting. Two recent studies by CHERISH researchers modeled economic and health outcomes for PWID and found evidence of synergistic benefits […]

June 3, 2019 Research Highlight

Buprenorphine for Opioid Use Disorder Lowers Overdose Risk in Commercially Insured Individuals

“Medications for opioid use disorder saves lives.” That’s the title and conclusion of a recent report by the National Academies of Sciences, Engineering and Medicine, based on a review of the scientific evidence. In a new study in Drug and Alcohol Dependence, CHERISH investigators Jake Morgan, Bruce Schackman and Benjamin Linas add to this evidence base by […]

May 14, 2019 Research Highlight

Neonatal Abstinence Syndrome and the Opioid Crisis: Paying Attention to Social Context

As you likely continue to read in your local news or experience in your community, the United States is in the midst of a deadly drug overdose and addiction crisis. In fact, overdoses claimed the lives of 70,000 individuals in 2017—more than two-thirds of those overdoses were linked to opioids. While drug overdoses disproportionately affect young adults, there […]

March 15, 2019 Research Highlight

Starting Opioid Use Disorder Treatment in the Emergency Department: Physician-reported barriers and facilitators

Every day, we hear about the staggering toll of the opioid overdose crisis. This is particularly salient in Philadelphia, which has one of the highest overdose death rates among major U.S. cities. Despite effective medications for opioid use disorder, such as buprenorphine and methadone, few people receive treatment. The ongoing challenge is to expand access to these lifesaving treatments […]

Engage with CHERISH

Submit a Consultation Request or Contact Us to learn more about how CHERISH can support your research or policy goals.